PARNETTI, Lucilla
 Distribuzione geografica
Continente #
EU - Europa 123
NA - Nord America 33
AS - Asia 5
OC - Oceania 1
SA - Sud America 1
Totale 163
Nazione #
IT - Italia 65
US - Stati Uniti d'America 32
IE - Irlanda 23
RO - Romania 15
DE - Germania 11
CH - Svizzera 3
GB - Regno Unito 3
IN - India 3
IL - Israele 2
PL - Polonia 2
AU - Australia 1
BR - Brasile 1
CA - Canada 1
SI - Slovenia 1
Totale 163
Città #
Perugia 44
Dublin 23
Bucharest 15
Fleming Island 8
Milan 3
Basel 2
Berlin 2
Council Bluffs 2
Formigine 2
Krakow 2
Munich 2
Tel Aviv 2
Worcester 2
Ambli 1
Boardman 1
Bochum 1
Bologna 1
Brooklyn 1
Byron 1
Devizes 1
Freienbach 1
Harrisonburg 1
Iffeldorf 1
Kamloops 1
Menges 1
Parma 1
Ponte 1
Rome 1
Stuttgart 1
Sumaré 1
Sydney 1
Verona 1
Totale 128
Nome #
Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease, file e3aa2010-30e1-ebae-e053-6605fe0a5b79 37
Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies, file e3aa200c-a032-ebae-e053-6605fe0a5b79 12
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease, file e3aa200e-a6d3-ebae-e053-6605fe0a5b79 10
Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies, file e3aa200f-26bb-ebae-e053-6605fe0a5b79 10
Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids, file e3aa200e-a1eb-ebae-e053-6605fe0a5b79 8
Therapeutic potential of autophagy-enhancing agents in Parkinson's disease, file e3aa200f-0bd3-ebae-e053-6605fe0a5b79 8
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation, file e3aa2010-70ce-ebae-e053-6605fe0a5b79 8
Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies, file e3aa200e-a1e2-ebae-e053-6605fe0a5b79 5
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis, file e3aa200e-a6ce-ebae-e053-6605fe0a5b79 4
Parkinson's and Lewy body dementia CSF biomarkers, file e3aa200e-a6d5-ebae-e053-6605fe0a5b79 4
CSF and blood biomarkers for Parkinson's disease, file e3aa200f-a84f-ebae-e053-6605fe0a5b79 4
Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients, file e3aa2010-e3a5-ebae-e053-6605fe0a5b79 4
Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation, file e3aa200c-a229-ebae-e053-6605fe0a5b79 3
The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease, file e3aa200e-a6d1-ebae-e053-6605fe0a5b79 3
Neuroendocrine markers in aging brain: clinical and neurobiological significance of dexamethasone suppression test, file e3aa200b-8aff-ebae-e053-6605fe0a5b79 2
No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF, file e3aa200c-a38b-ebae-e053-6605fe0a5b79 2
Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease, file e3aa200e-c1d9-ebae-e053-6605fe0a5b79 2
CSF monoamine metabolites in old age dementias., file e3aa200e-e145-ebae-e053-6605fe0a5b79 2
Long-Term Risk of Stroke After Transient Global Amnesia in Two Prospective Cohorts, file e3aa200f-7777-ebae-e053-6605fe0a5b79 2
Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies, file e3aa200f-dffd-ebae-e053-6605fe0a5b79 2
Association of cerebral amyloid-β Aggregation with cognitive functioning in persons without dementia, file e3aa2010-1a1d-ebae-e053-6605fe0a5b79 2
FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort, file e3aa2010-295e-ebae-e053-6605fe0a5b79 2
Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links, file e3aa2010-a46f-ebae-e053-6605fe0a5b79 2
The possible role of Optical Coherence Tomography (OCT) and OCT‐Angiography (OCTA) as new non‐invasive biomarkers of prodromal Alzheimer’s disease, file e3aa2011-4aa9-ebae-e053-6605fe0a5b79 2
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease, file 4aad4d2e-2aec-4a1e-9bb4-671f5009702d 1
New insights into the genetic etiology of Alzheimer's disease and related dementias, file 4ef9fa83-235f-4367-a589-7cfa65442705 1
White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers, file 6e0ab44d-9963-46d5-b7c5-5300c6269715 1
Neuropsychological results of long-term therapy with oxiracetam in DAT/MID patients in comparison with a control group, file e3aa200b-3663-ebae-e053-6605fe0a5b79 1
Cerebrospinal fluid biomarkers in Parkinson disease., file e3aa200c-4a73-ebae-e053-6605fe0a5b79 1
Origin of α-mannosidase activity in CSF, file e3aa200d-932e-ebae-e053-6605fe0a5b79 1
Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis, file e3aa200d-adc3-ebae-e053-6605fe0a5b79 1
Are we ready for detecting α-synuclein prone to aggregation in patients? The case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as diagnostic tools, file e3aa200e-0a8e-ebae-e053-6605fe0a5b79 1
Is multi-infarct dementia representative of vascular dementias? A retrospective study, file e3aa200e-ce5e-ebae-e053-6605fe0a5b79 1
Effect of acetyl-L-carnitine on serum levels of cortisol and adrenocorticotropic hormone and its clinical effect in patients with senile dementia of Alzheimer type, file e3aa200e-cf55-ebae-e053-6605fe0a5b79 1
Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias., file e3aa200e-e04d-ebae-e053-6605fe0a5b79 1
Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type., file e3aa200e-e051-ebae-e053-6605fe0a5b79 1
Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias, file e3aa200e-e149-ebae-e053-6605fe0a5b79 1
Cognitive enhancement therapy for Alzheimer's disease. The way forward., file e3aa200e-e14f-ebae-e053-6605fe0a5b79 1
Pathogenetic mechanisms in vascular dementia, file e3aa200e-e274-ebae-e053-6605fe0a5b79 1
Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia., file e3aa200e-e3f3-ebae-e053-6605fe0a5b79 1
Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease, file e3aa200f-1df8-ebae-e053-6605fe0a5b79 1
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders, file e3aa200f-5dec-ebae-e053-6605fe0a5b79 1
null, file e3aa200f-6a1c-ebae-e053-6605fe0a5b79 1
Prevalence and risk of progression of preclinical Alzheimer's disease stages: A systematic review and meta-analysis, file e3aa200f-a175-ebae-e053-6605fe0a5b79 1
Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI), file e3aa2010-05aa-ebae-e053-6605fe0a5b79 1
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia, file e3aa2010-3239-ebae-e053-6605fe0a5b79 1
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis, file e3aa2010-3e4e-ebae-e053-6605fe0a5b79 1
Totale 163
Categoria #
all - tutte 454
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 454


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203 0 0 0 0 0 0 0 0 2 0 1 0
2020/202116 0 0 0 2 0 0 0 5 2 7 0 0
2021/202245 0 0 0 0 0 0 0 0 2 19 15 9
2022/202368 0 0 0 3 3 9 8 7 26 8 4 0
2023/202427 3 4 7 1 2 4 0 2 4 0 0 0
Totale 163